Investigated for treating COVID-19.
Budesonide–MMX is an oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon.
Symbicort is budesonide and formoterol.
- TRADE NAMES: Pulmicort Turbuhaler (AstraZeneca); Rhinocort (AstraZeneca); Symbicort (AstraZeneca)
- INDICATIONS: Asthma, rhinitis
- CLASS: Corticosteroid / Glucocorticoid, Corticosteroid, inhaled
- HALF-LIFE: N/A
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Boceprevir, Efavirenz, Itraconazole, Ketoconazole, Live vaccines, Oral Contraceptives, Telaprevir
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see reviews of budesonide–MMX in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/01/2025
